Clinical Trial Update: Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM [Phase 2]

View source ↗

Summary

A Phase II trial evaluating the combination of bendamustine, dexamethasone, and thalidomide for relapsed/refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bendamustine (Bendamustine)
• DEXAMETHASONE (Dexamethasone)
• Thalidomide (thalidomide)

Snippet

Sponsor: Azienda Ospedaliera di Bolzano | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED